Answers are grounded in this paper and cite their sources.
INTRODUCTION: The lamivudine (3TC) + stavudine (d4T) combination is still widely used as part of first-line therapy for HIV-1-infected patients in low-resource countries. This review is intended to assess the benefits and risks in terms of safety of d4T + 3TC-based combination antiretroviral therapy (ART) for the treatment of HIV-1 infection. AREAS COVERED: The most relevant papers related to the safety of d4T + 3TC-based ART were selected and summarized. EXPERT OPINION: In industrialized countries, the 3TC + d4T combination is not recommended for initial therapy because of long-term metabolic toxicities associated with d4T. In developing countries, it may have a role in the treatment of HIV-infected patients if there is no other chance for starting antiretroviral therapy.
No takes yet. Share an insight, caveat, or question.
Mateo et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: